Corcept Therapeutics Incorporated Stock Today
| CORT Stock | USD 57.54 1.62 2.90% |
Performance22 of 100
| Odds Of DistressLess than 3
|
Corcept Therapeutics is selling for under 57.54 as of the 25th of November 2024; that is 2.90 percent increase since the beginning of the trading day. The stock's last reported lowest price was 56.14. Corcept Therapeutics has a very small chance of experiencing financial distress in the next few years and had a solid performance during the last 90 days. Equity ratings for Corcept Therapeutics Incorporated are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 1st of December 2023 and ending today, the 25th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 14th of April 2004 | Category Healthcare | Classification Health Care |
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California. The company has 104.78 M outstanding shares of which 18.8 M shares are currently shorted by private and institutional investors with about 17.04 trading days to cover. More on Corcept Therapeutics Incorporated
Moving against Corcept Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Corcept Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President Oncology | Roberto Vieira | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, SP Small-Cap 600, ARCA Biotechnology, NASDAQ Composite, NASDAQ Health Care, NASDAQ Composite Total, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsCorcept Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Corcept Therapeutics' financial leverage. It provides some insight into what part of Corcept Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Corcept Therapeutics Incorporated (CORT) is traded on NASDAQ Exchange in USA. It is located in 149 Commonwealth Drive, Menlo Park, CA, United States, 94025 and employs 352 people. Corcept Therapeutics is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 6.03 B. Corcept Therapeutics conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 104.78 M outstanding shares of which 18.8 M shares are currently shorted by private and institutional investors with about 17.04 trading days to cover.
Corcept Therapeutics Incorporated currently holds about 370.09 M in cash with 127.04 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.45.
Check Corcept Therapeutics Probability Of Bankruptcy
Ownership AllocationCorcept Therapeutics holds a total of 104.78 Million outstanding shares. The majority of Corcept Therapeutics Incorporated outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Corcept Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Corcept Therapeutics. Please pay attention to any change in the institutional holdings of Corcept Therapeutics Incorporated as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Corcept Ownership Details
Corcept Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Btim Corp | 2024-09-30 | 1.5 M | |
| Arrowstreet Capital Limited Partnership | 2024-06-30 | 1.5 M | |
| Fmr Inc | 2024-09-30 | 1.4 M | |
| Jacobs Levy Equity Management, Inc. | 2024-09-30 | 1.2 M | |
| Charles Schwab Investment Management Inc | 2024-09-30 | 1 M | |
| Northern Trust Corp | 2024-09-30 | 921.4 K | |
| Norges Bank | 2024-06-30 | 822.1 K | |
| D. E. Shaw & Co Lp | 2024-09-30 | 788.1 K | |
| Connor Clark & Lunn Inv Mgmt Ltd | 2024-06-30 | 716.1 K | |
| Blackrock Inc | 2024-06-30 | 16.5 M | |
| Vanguard Group Inc | 2024-09-30 | 10 M |
Corcept Therapeutics Historical Income Statement
Corcept Stock Against Markets
Corcept Therapeutics Corporate Management
| Hazel Hunt | Chief Officer | Profile | |
| Amy Flood | Chief Officer | Profile | |
| Joseph MD | President, CoFounder | Profile | |
| William PharmD | Chief Officer | Profile | |
| Gary JD | Chief Secretary | Profile |
Additional Tools for Corcept Stock Analysis
When running Corcept Therapeutics' price analysis, check to measure Corcept Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corcept Therapeutics is operating at the current time. Most of Corcept Therapeutics' value examination focuses on studying past and present price action to predict the probability of Corcept Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corcept Therapeutics' price. Additionally, you may evaluate how the addition of Corcept Therapeutics to your portfolios can decrease your overall portfolio volatility.